SG43365A1 - B-adrenergic agonists - Google Patents

B-adrenergic agonists

Info

Publication number
SG43365A1
SG43365A1 SG1996009751A SG1996009751A SG43365A1 SG 43365 A1 SG43365 A1 SG 43365A1 SG 1996009751 A SG1996009751 A SG 1996009751A SG 1996009751 A SG1996009751 A SG 1996009751A SG 43365 A1 SG43365 A1 SG 43365A1
Authority
SG
Singapore
Prior art keywords
adrenergic agonists
adrenergic
agonists
Prior art date
Application number
SG1996009751A
Other languages
English (en)
Inventor
Robert Lee Dow
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG43365A1 publication Critical patent/SG43365A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
SG1996009751A 1995-05-10 1996-05-07 B-adrenergic agonists SG43365A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB1995/000344 WO1996035671A1 (en) 1995-05-10 1995-05-10 β-ADRENERGIC AGONISTS
CA002220399A CA2220399A1 (en) 1995-05-10 1995-05-10 .beta.-adrenergic agonists
HU9601240A HUP9601240A1 (en) 1995-05-10 1996-05-09 Pyridin and pyrimidin derivatives, suitable as beta-adrenerg agonists, pharmaceutical compositions containing the same and their intermediates

Publications (1)

Publication Number Publication Date
SG43365A1 true SG43365A1 (en) 1997-10-17

Family

ID=89993954

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996009751A SG43365A1 (en) 1995-05-10 1996-05-07 B-adrenergic agonists

Country Status (19)

Country Link
US (1) US5977124A (es)
EP (1) EP0824519A1 (es)
JP (1) JPH11504649A (es)
KR (1) KR100190259B1 (es)
AU (1) AU706235B2 (es)
BR (1) BR9602209A (es)
CA (1) CA2220399A1 (es)
CO (1) CO4440567A1 (es)
CZ (1) CZ132196A3 (es)
FI (1) FI974172A (es)
HU (1) HUP9601240A1 (es)
IL (1) IL118115A0 (es)
MX (1) MX9708621A (es)
NO (1) NO307049B1 (es)
NZ (1) NZ286548A (es)
PL (1) PL314120A1 (es)
SG (1) SG43365A1 (es)
TR (1) TR199600358A2 (es)
WO (1) WO1996035671A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6008361A (en) * 1996-04-09 1999-12-28 Pfizer Inc. Substituted pyridines
US6031105A (en) * 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
TR199901063T2 (xx) 1996-11-14 1999-08-23 Pfizer Inc. �kame edilmi� piridinler i�in i�lem.
US6001856A (en) * 1997-06-13 1999-12-14 Pfizer Inc. β-adrenergic agonists to reduce a wasting condition
EP0920864A1 (en) * 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US6657063B1 (en) * 1998-04-30 2003-12-02 Pfizer Inc. Combinations of β3 agonists and growth hormone secretagogues
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
ATE280167T1 (de) 1999-07-23 2004-11-15 Pfizer Prod Inc Zwischenprodukte und ein verfahren zur herstellung von beta3-adrenergischer rezeptor- agoniste
WO2001021577A2 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
US6451587B1 (en) 1999-09-29 2002-09-17 Pfizer Inc. Microbial asymmetric reduction of 2-chloro-1-[-6-(2,5-dimethyl-pyrrol-1-yl)-pyridin-3-yl]-ethanone
AU5257401A (en) * 2000-04-28 2001-11-12 Asahi Chemical Ind Novel bicyclic compounds
AP2001002307A0 (en) * 2000-10-20 2001-12-31 Pfizer Prod Inc B3 adrenergic receptor agonists and uses thereof.
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
WO2003072547A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. PROCESSES AND INTERMEDIATES USEFUL IN PREPARING β3-ADRENERGIC RECEPTOR AGONISTS
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
DOP2003000587A (es) * 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
US20050075323A1 (en) * 2003-03-05 2005-04-07 Pfizer Inc Beta3 adrenergic receptor agonists and uses thereof
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
US7375100B2 (en) 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
GB0312832D0 (en) * 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
CN100582088C (zh) * 2003-12-23 2010-01-20 安斯泰来制药有限公司 氨基醇衍生物
WO2006051373A1 (en) * 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
EP1888101B1 (en) 2005-06-06 2012-03-21 Georgetown University Compositions and methods for lipo modeling
BRPI0903206E2 (pt) 2009-09-01 2015-07-28 Da Silva Antonio Carlos Nunes Ett Unidade processadora e método de processamento de fraldas e absorventes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) * 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
EP0105053B1 (en) * 1982-10-01 1988-01-20 Merck & Co. Inc. Aralkylaminoethanol heterocyclic compounds
CA1287061C (en) * 1986-06-27 1991-07-30 Roche Holding Ltd. Pyridine ethanolamine derivatives
GB8703007D0 (en) * 1987-02-10 1987-03-18 Glaxo Group Ltd Chemical compounds
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
US5216170A (en) * 1989-01-26 1993-06-01 Bayer Aktiengesellschaft (2-aminopropyl) pyridines useful as intermediates
GB9209076D0 (en) * 1992-04-27 1992-06-10 Ici Plc Chemical compounds
WO1994008945A1 (de) * 1992-10-16 1994-04-28 Byk Nederland Bv Substituierte ethanolaminester
JPH08505846A (ja) * 1992-12-29 1996-06-25 スミスクライン・ビーチャム・コーポレイション 血小板凝集阻害用化合物
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
JPH08509491A (ja) * 1993-04-26 1996-10-08 藤沢薬品工業株式会社 胃腸疾患の治療に有用なエタノールアミン誘導体
PL312005A1 (en) * 1993-06-14 1996-04-01 Pfizer Binary amines as antidiabetic and antiobesitic agents
JPH08165276A (ja) * 1994-12-14 1996-06-25 Dainippon Pharmaceut Co Ltd 2−アルキルアミノ−1−フェニルエタノール誘導体

Also Published As

Publication number Publication date
NO307049B1 (no) 2000-01-31
CA2220399A1 (en) 1996-11-14
MX9708621A (es) 1998-02-28
AU5218596A (en) 1996-11-21
CZ132196A3 (en) 1997-03-12
IL118115A0 (en) 1996-09-12
CO4440567A1 (es) 1997-05-07
FI974172A0 (fi) 1997-11-07
AU706235B2 (en) 1999-06-10
HU9601240D0 (en) 1996-07-29
JPH11504649A (ja) 1999-04-27
TR199600358A2 (tr) 1996-11-21
FI974172A (fi) 1997-11-07
BR9602209A (pt) 1998-04-07
WO1996035671A1 (en) 1996-11-14
PL314120A1 (en) 1996-11-12
NZ286548A (en) 1998-03-25
HUP9601240A1 (en) 1997-09-29
KR100190259B1 (ko) 1999-06-01
KR960041168A (ko) 1996-12-19
US5977124A (en) 1999-11-02
NO961887D0 (no) 1996-05-09
NO961887L (no) 1996-11-11
EP0824519A1 (en) 1998-02-25

Similar Documents

Publication Publication Date Title
SG43365A1 (en) B-adrenergic agonists
FI974170A (fi) B-adrenergisiä agonisteja
GB2313583B (en) Mooring assembly
GB2307306B (en) Stereo-slide mount
DE59505396D1 (en) Handhobelmaschine
GB9505424D0 (en) Hydrogels
AP9600802A0 (en) Libricant
HUP9801745A3 (en) Sorbic-acid-containing hydrogels
GB9525560D0 (en) Locking-swivel mount
CA77215S (en) Buoy
CA77430S (en) Mount
AU1105P (en) DALESE Metrosideros excelsus
GB9503528D0 (en) Hydrogels
GB9526298D0 (en) Hydrogels
GB9526297D0 (en) Hydrogels
GB9503506D0 (en) Hydrogels
GB9526362D0 (en) Hydrogels
GB9526363D0 (en) Hydrogels
GB9513743D0 (en) Hydrogels
GB9518880D0 (en) Hydrogels
GB9521506D0 (en) Hydrogels
GB9526299D0 (en) Hydrogels
GB9503507D0 (en) Hydrogels
AU125922S (en) Pivot
GB9518979D0 (en) Mx - l i j